FAP and neoplasm: FAP‐targeted radioligand therapy with 177Lu–LNC1004 at 3.33 GBq per cycle was well tolerated in patients with advanced mRAIR–TC, delivering a high radiation dose to tumor lesions, which encouraged therapeutic efficacy while maintaining acceptable side effects.